HONG KONG – With a $15 million seed round closed last month, young biotech firm Cullgen Inc. is looking to build a new drug discovery platform based on advanced ubiquitin-mediated protein degradation technology.
HONG KONG – With a $15 million seed round closed last month, young biotech firm Cullgen Inc. is looking to build a new drug discovery platform based on advanced ubiquitin-mediated protein degradation technology.
HONG KONG – Japan's Carna Biosciences Inc. and Sumitomo Dainippon Pharma Co. Ltd. signed an agreement potentially worth about $100 million to work together on the research, development and commercialization of novel kinase inhibitors, focusing on psychiatric and neurological disorders.
HONG KONG – Travecta Therapeutics Pte Ltd. is the latest startup to join Singapore's biotech block. The newly formed drug discovery company is based on intellectual property derived from discoveries made at Duke-NUS Medical School (Duke-NUS).
HONG KONG – Travecta Therapeutics Pte Ltd. is the latest startup to join Singapore's biotech block. The newly formed drug discovery company is based on intellectual property derived from discoveries made at Duke-NUS Medical School (Duke-NUS).
HONG KONG –LG Chem Ltd. recently received marketing approval for Eucept, its etanercept biosimilar, from South Korea's Ministry of Food and Drug Safety. Based on Amgen Inc. and Pfizer Inc.'s blockbuster biologic, Enbrel, the approval for Eucept is significant for LG Chem, marking the first monoclonal antibody it has developed.
